US cancels more $700 million funding for Moderna bird flu vaccine

Moderna's contract, initially awarded $590 million by the Biden administration in January for late-stage development of its bird flu vaccine, has been cancelled by the Trump administration, along with the right to purchase shots; this follows a prior $176 million award from the U.S. Department of Health and Human Services. Moderna plans to explore alternative options for the vaccine's late-stage development and manufacturing, coinciding with positive interim data from a mid-stage trial assessing the vaccine's safety and immunogenicity against the H5 avian influenza virus subtype.

Analysis

Moderna (MRNA) faces a significant development setback as the Trump administration has cancelled a contract for the late-stage development of its human bird flu vaccine, which included rights to purchase doses. This contract, initially awarded $590 million by the Biden administration in January and supplemented by a previous $176 million from the U.S. Department of Health and Human Services, was crucial for advancing the vaccine. The cancellation introduces uncertainty regarding the timeline and funding for this specific program, reflected in the moderately negative sentiment score of -0.4 for MRNA. Despite this contract loss, Moderna intends to explore alternative pathways for the vaccine's late-stage development and manufacturing. Concurrently, the company announced positive interim data from a mid-stage trial for its H5 avian influenza virus subtype vaccine, demonstrating favorable safety and immunogenicity. This scientific progress offers a partial counter-narrative to the funding disruption, though the market impact score of 0.55 suggests a notable event for the stock.

Key Decisions for Investors

• Investors should closely monitor Moderna's ability to secure alternative funding or partnerships for the late-stage development and manufacturing of its bird flu vaccine following the contract cancellation.
• The positive mid-stage trial data for the H5 vaccine is encouraging, but its commercial prospects may be tempered by the loss of the government contract; assess the balance between scientific progress and increased execution risk.
• Re-evaluate revenue projections related to the bird flu vaccine pipeline and consider the potential for increased R&D expenditure or delays in bringing this specific vaccine to market.